🚀 This program focused on the Cell Shuttle™ for the automation of Cabaletta’s rese-cel therapy, targeting autoimmune diseases.
🌍 Both companies aim to streamline global manufacturing and enhance patient access to these therapies rapidly.
🤝 The collaboration promises efficient production and delivery of potentially curative treatments for a large patient population.
Introduction:
The article discusses the completion of the Technology Adoption Program (TAP) by Cellares, an Integrated Development and Manufacturing Organization (IDMO), for its automated cell therapy manufacturing system, the Cell Shuttle™, specifically for the production of Cabaletta Bio’s rese-cel, a targeted CAR T cell therapy designed for autoimmune diseases.
- Cellares successfully concluded its Technology Adoption Program (TAP) for the Cell Shuttle™ system, assessing its feasibility for automated manufacturing of Cabaletta Bio’s rese-cel product.
- The TAP demonstrated the capability of the Cell Shuttle to concurrently manufacture multiple batches of rese-cel, highlighting its efficiency.
- There are plans to manufacture current Good Manufacturing Practice (cGMP) cell therapy batches to meet patient needs.
- The partnership aims to facilitate the global expansion of rese-cel through rapid technology transfer to additional IDMO Smart Factories, potentially addressing a larger patient population across multiple autoimmune conditions.
- The success of the TAP serves as proof of concept for the Cell Shuttle as a scalable and cost-effective platform for cell therapy production, supporting small biotech companies in advancing manufacturing capabilities.
Conclusion:
The completion of the TAP emphasizes the potential of automated cell manufacturing systems like the Cell Shuttle™ to revolutionize the production of CAR T cell therapies. This initiative not only promises to improve manufacturing efficiency and lower costs but also represents a significant step towards expanding access to potentially curative therapies for patients suffering from autoimmune diseases. Future collaborations between Cellares and Carabatta Bio may set new standards in biomanufacturing and patient care.
